この記事を読む

ALTA-2:アレクチニブ後のブリグチニブ

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lun…

この記事を読む

ICI化学療法終了後のラムシルマブ+アテゾリズマブ

Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkp…

この記事を読む

肺癌患者へのブースター接種後のオミクロン株に対する抗体の推移

Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivi…

この記事を読む

肺癌治療の進歩にもかかわらず、まだ気管支漏には対処が難しい

Bronchorrhea, a Rare and Debilitating Symptom of Lung Cancer: Case Report and Review of the Treatment. Bhagat M et al.JT…

この記事を読む

PETによる原発巣と転移巣の効果判定の不一致

18F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-…

この記事を読む

ペムブロリズマブ3週から6週間隔への変更でirAEが増える可能性

Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With…

この記事を読む

ICIの長期成績、日本人の実地データで4生率17.9%

Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in R…

この記事を読む

小細胞肺癌に対する免疫療法の実地データ

Real-world evidence for immunotherapy in the first line setting in small cell lung cancer Shira Sagie et al.lung Cancer …

この記事を読む

ヒスパニック系におけるオシメルチニブの耐性機序

Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRE…

この記事を読む

低分化型腺癌と腫瘍微小環境との関連

Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic t…